indazoles has been researched along with Colorectal Neoplasms in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.94) | 18.7374 |
| 1990's | 2 (5.88) | 18.2507 |
| 2000's | 4 (11.76) | 29.6817 |
| 2010's | 23 (67.65) | 24.3611 |
| 2020's | 4 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Alburquerque-González, B; Bernabé-García, Á; Bernabé-García, M; Cayuela, ML; Conesa-Zamora, P; den-Haan, H; Luque, I; Montoro-García, S; Nicolás, FJ; Pérez-Sánchez, H; Rodrigues, PC; Salo, T | 1 |
| André, T; Cohen, R; Ouali, K; Pellat, A; Penault-Llorca, F; Svrcek, M | 1 |
| Belli, V; Cardone, C; Ciardiello, D; Ciardiello, F; De Falco, V; Della Corte, C; Desiderio, V; Giunta, EF; Martinelli, E; Martini, G; Matrone, N; Mele, L; Morgillo, F; Napolitano, S; Papaccio, G; Poliero, L; Selvaggi, F; Tirino, V; Troiani, T; Vitiello, PP | 1 |
| Bin, L; Furukawa, T; Gazi, MY; Hatsuzawa, Y; Ito, S; Kajiwara, T; Kamei, T; Karasawa, H; Katsuoka, F; Kobayashi, M; Kumada, K; Ohnuma, S; Okamura, Y; Sato, M; Shiihara, M; Shimada, M; Suzuki, H; Tayama, H; Unno, M; Yamamura, A | 1 |
| Ancell, K; Berlin, JD; Cardin, DB; Chan, E; Goff, LW; Smith, SJ; Whisenant, JG; Ye, F | 1 |
| Amatu, A; Bardelli, A; Bartolini, A; Buscarino, M; Cassingena, A; Corti, G; Crisafulli, G; Di Nicolantonio, F; Erlander, M; Mussolin, B; Novara, L; Sartore-Bianchi, A; Siena, S; Siravegna, G; Tosi, F | 1 |
| Barnes, K; Bendell, JC; Blachly, R; Blakely, L; Earwood, C; Joseph, M; Kuzur, M; Lane, CM; Mainwaring, M; Reddy, C; Shipley, D | 1 |
| Dai, J; Hu, Y; Li, X; Wang, Y; Williams, BR; Xu, D; Xu, P; Yan, F; Ying, L; Zhao, Y | 1 |
| Dang, KX; Haglund, C; Ho, TH; Koistinen, H; Lintula, S; Mustonen, H; Räsänen, K; Stenman, J; Stenman, UH | 1 |
| Liu, Y; Lyu, J; Miao, Z; Poon, TCW; Shim, JS; Tan, K; Wu, C; Yang, EJ; Zhang, B | 1 |
| Birnbaum, A; Cohen, RB; Denlinger, CS; Giles, J; He, AR; Hwang, J; Lewis, N; Moser, B; Mynderse, M; Niland, M; Plimack, ER; Sama, A; Sato, T; Walgren, R; Wallin, J; Zhang, W | 1 |
| Adams, LM; Botbyl, J; Brady, J; Chau, I; Corrie, P; Digumarti, R; Laubscher, KH; Mallath, M; Midgley, RS | 1 |
| Cartwright, TH; Cescon, TP; Cohn, AL; Edenfield, WJ; Hamm, JT; Infante, JR; Kim, S; Malik, IA; McGee, PJ; Rado, TA; Reid, TR; Richards, DA; Rosbrook, B; Tarazi, J | 1 |
| Barone, C; Bendell, JC; Bloom, J; Kim, JG; Kim, S; Pastorelli, D; Pericay, C; Ricart, AD; Rosbrook, B; Sobrero, AF; Swieboda-Sadlej, A; Tarazi, J; Tournigand, C; Wainberg, ZA | 1 |
| Haagensen, EJ; Harnor, SJ; Maxwell, RJ; Newell, DR; Payne, SL; Rennison, T; Smith, KM; Thomas, HD; Wilson, I | 1 |
| Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ | 1 |
| Berlin, J; Cainap, C; Carlson, DM; Fischer, J; Goldberg, RM; Gorbunova, V; Karapetis, CS; Kim, TW; McKee, MD; O'Neil, BH; Qian, J; Qin, Q; Ricker, JL; Van Cutsem, E | 1 |
| Bennouna, J; Botbyl, J; de Labareyre, C; Delord, JP; Deslandres, M; Ruiz-Soto, R; Senellart, H; Suttle, AB; Wixon, C | 1 |
| Ali, SM; Balasubramanian, S; Do, IG; Hong, JY; Hornby, Z; Huh, JW; Jang, J; Kang, WK; Kim, HC; Kim, KM; Kim, SH; Kim, ST; Kim, SY; Lee, J; Lee, WY; Li, GG; Lim, HY; Miller, VA; Ou, SH; Park, JO; Park, YA; Park, YS; Ross, JS; Stephens, PJ; Wang, K; Yun, SH | 1 |
| Ceelen, W; De Wever, O; Descamps, B; Gremonprez, F; Izmer, A; Vanhaecke, F; Vanhove, C | 1 |
| Ahn, SM; Christiansen, J; Hong, ME; Hong, SN; Hornby, Z; Jang, J; Kang, WK; Kim, KM; Kim, SH; Kim, ST; Lee, DW; Lee, J; Lee, SJ; Li, GG; Lim, HY; Murphy, D; Park, JO; Park, K; Park, WY; Park, YS; Wei, G; Yoon, N | 1 |
| Bardelli, A; Bartolini, A; Bianchi, AS; Cam, N; Corti, G; Crisafulli, G; Di Nicolantonio, F; Lazzari, L; Li, G; Misale, S; Mussolin, B; Novara, L; Patel, R; Rospo, G; Russo, M; Shoemaker, R; Siena, S; Siravegna, G; Wei, G; Wild, R; Yan, S | 1 |
| Amatu, A; Ardini, E; Bosotti, R; Buonandi, P; Cerea, G; Galvani, A; Giannetta, L; Hornby, Z; Isacchi, A; Lauricella, C; Luo, D; Maiolani, M; Marrapese, G; Multani, P; Murphy, D; Sartore-Bianchi, A; Shoemaker, R; Siena, S; Somaschini, A; Valtorta, E; Vanzulli, A; Veronese, S | 1 |
| Blagg, J; Busch, M; Czodrowski, P; Eccles, SA; Esdar, C; Mallinger, A; Musil, D; Poeschke, O; Raynaud, FI; Rohdich, F; Schiemann, K; Schneider, R; Schwarz, D; Urbahns, K; Wienke, D | 1 |
| Amboldi, N; Anderson, D; Ardini, E; Avanzi, N; Ballinari, D; Bandiera, T; Banfi, P; Bosotti, R; Casero, D; Ciomei, M; De Ponti, C; Degrassi, A; Donati, D; Felder, E; Galvani, A; Harris, J; Isacchi, A; Li, G; Magnaghi, P; Menichincheri, M; Mologni, L; Orsini, P; Pesenti, E; Pulci, R; Saccardo, MB; Texido, G; Vernier, JM; Wei, G | 1 |
| Abhyankar, V; Burgess, RE; Chen, Y; Infante, J; Kim, S; Robles, RL; Sharma, S; Tarazi, J; Tortorici, M; Trowbridge, RC | 1 |
| Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S | 1 |
| Berger, W; Heffeter, P; Jakupec, MA; Kapitza, S; Keppler, BK; Lackinger, L; Marian, B; Pongratz, M | 1 |
| Jakupec, MA; Kapitza, S; Keppler, BK; Marian, B; Uhl, M | 1 |
| Kibble, A | 1 |
| Ferris, AM; LoRusso, PM; Philip, PA; Shields, AF; Zalupski, MM | 1 |
| Abbruzzese, JL; Dakhil, SR; Ellerton, JA; Hoff, PM; Pazdur, R; Winn, RJ | 1 |
| Berger, MR; Keppler, BK; Seelig, MH | 1 |
| Basurto, C; Bertusi, M; Bisagni, G; Buzzi, F; Di Costanzo, F; Donati, D; Gori, S; Passalacqua, R | 1 |
3 review(s) available for indazoles and Colorectal Neoplasms
| Article | Year |
|---|---|
[NTRK Fusions: A new way of treatment for gastro-intestinal tumor?]
Topics: Benzamides; Colorectal Neoplasms; Gastrointestinal Neoplasms; Gene Fusion; High-Throughput Nucleotide Sequencing; Humans; Immunohistochemistry; In Situ Hybridization; Indazoles; Membrane Glycoproteins; Nerve Growth Factors; Oncogene Proteins; Oncogene Proteins, Fusion; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, trkA; Receptor, trkB; Receptor, trkC | 2020 |
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
12 trial(s) available for indazoles and Colorectal Neoplasms
| Article | Year |
|---|---|
Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS.
Topics: Adult; Aged; Angiogenesis Inhibitors; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Tomography, X-Ray Computed; Treatment Outcome | 2017 |
A Phase-2 Trial of Single Agent Axitinib as Maintenance Therapy Following First-Line Treatment With Modified FOLFOX/Bevacizumab in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Treatment Outcome | 2017 |
First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Proliferation; Cetuximab; Cholangiocarcinoma; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Indazoles; Male; Middle Aged; Neoplasm Staging; Niacinamide; Protein Kinase Inhibitors; Ramucirumab; Squamous Cell Carcinoma of Head and Neck | 2019 |
An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Indazoles; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Infusions, Intravenous; Injections, Intravenous; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Treatment Outcome | 2013 |
Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Young Adult | 2013 |
Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Hypothyroidism; Indazoles; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Phenylurea Compounds; Survival Rate; Thrombocytopenia; Young Adult | 2014 |
A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Sulfonamides; Topoisomerase I Inhibitors; Treatment Outcome | 2015 |
A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Treatment Outcome | 2010 |
Phase II study of CI-958 in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Indazoles; Intercalating Agents; Leukopenia; Male; Middle Aged | 1999 |
Phase II study of intravenous CI-958 in metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Humans; Indazoles; Infusions, Intravenous; Male; Middle Aged | 2000 |
Lonidamine in advanced colorectal cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC).
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Clinical Trials as Topic; Colorectal Neoplasms; Drug Evaluation; Female; Humans; Indazoles; Italy; Male; Middle Aged; Neoplasm Metastasis; Pyrazoles | 1989 |
19 other study(ies) available for indazoles and Colorectal Neoplasms
| Article | Year |
|---|---|
Novel anti-invasive properties of a Fascin1 inhibitor on colorectal cancer cells.
Topics: Animals; Antineoplastic Agents; Carrier Proteins; Cell Line, Tumor; Cell Movement; Cell Survival; Colorectal Neoplasms; Embryo, Nonmammalian; Humans; Indazoles; Microfilament Proteins; Models, Molecular; Neoplasm Invasiveness; Zebrafish | 2020 |
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colorectal Neoplasms; Female; Humans; Indazoles; Irinotecan; Mice; Mice, Nude; Mutation; Piperidines | 2021 |
The association between ERK inhibitor sensitivity and molecular characteristics in colorectal cancer.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Enzyme Inhibitors; Exome Sequencing; Extracellular Signal-Regulated MAP Kinases; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Mutation; Organoids; Piperazines; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras) | 2021 |
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor.
Topics: Anaplastic Lymphoma Kinase; Aspartate Carbamoyltransferase; Benzamides; Biomarkers, Tumor; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Colorectal Neoplasms; Dihydroorotase; Drug Resistance, Neoplasm; Female; Gene Fusion; Gene Rearrangement; Humans; Indazoles; Middle Aged; Polymerase Chain Reaction; Receptor Protein-Tyrosine Kinases | 2017 |
(-)-Epigallocatechin-3-gallate and EZH2 inhibitor GSK343 have similar inhibitory effects and mechanisms of action on colorectal cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Catechin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Enhancer of Zeste Homolog 2 Protein; Humans; Indazoles; Neoplasm Invasiveness; Pyridones | 2018 |
MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
Topics: Activating Transcription Factor 4; Adenocarcinoma; Aged; Caco-2 Cells; Cell Line, Tumor; Cohort Studies; Colorectal Neoplasms; Female; HT29 Cells; Humans; Indazoles; Male; Middle Aged; Mitogen-Activated Protein Kinases; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Trypsin Inhibitor, Kazal Pancreatic | 2018 |
PTEN deficiency confers colorectal cancer cell resistance to dual inhibitors of FLT3 and aurora kinase A.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; HCT116 Cells; Humans; Indazoles; Mice, Nude; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrazoles; Pyrimidines; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice.
Topics: Animals; Antiviral Agents; Benzamides; Cell Line, Tumor; Colorectal Neoplasms; Dideoxynucleosides; Diphenylamine; Drug Synergism; Female; Heterografts; Humans; Indazoles; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Positron-Emission Tomography; Proto-Oncogene Proteins c-akt; Radiography; Sulfonamides | 2013 |
Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Benzamides; Cell Line, Tumor; Colorectal Neoplasms; Crizotinib; Female; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Rearrangement; Genomics; High-Throughput Nucleotide Sequencing; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Indazoles; Male; Middle Aged; Mutation; Phosphorylation; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Reproducibility of Results; Republic of Korea; Sensitivity and Specificity; Tissue Array Analysis; Young Adult | 2015 |
Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Extracellular Fluid; HT29 Cells; Humans; Imatinib Mesylate; Indazoles; Infusions, Parenteral; Mice; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Peritoneal Absorption; Peritoneum; Pressure; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Tumor Burden; Weight Loss; Xenograft Model Antitumor Assays | 2015 |
NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cell Line, Tumor; Colorectal Neoplasms; Female; Gene Rearrangement; Humans; Immunohistochemistry; Indazoles; Male; Middle Aged; Molecular Targeted Therapy; Prospective Studies; Receptor, trkA; Tumor Cells, Cultured | 2015 |
Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
Topics: Animals; Benzamides; Catalytic Domain; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Gene Rearrangement; Humans; Indazoles; Mice; Mutation; Neoplasm Transplantation; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Receptor, trkA | 2016 |
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Aspartate Carbamoyltransferase; Benzamides; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Colorectal Neoplasms; Dihydroorotase; Female; Gene Rearrangement; Humans; Indazoles; Middle Aged; Receptor Protein-Tyrosine Kinases | 2015 |
Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore.
Topics: Animals; Colorectal Neoplasms; Crystallography, X-Ray; Cyclin-Dependent Kinase 8; Dose-Response Relationship, Drug; Drug Discovery; HSP90 Heat-Shock Proteins; Humans; Indazoles; Mice; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Rats; Structure-Activity Relationship; Substrate Specificity | 2016 |
Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
Topics: Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Colorectal Neoplasms; Disease Models, Animal; Enzyme Activation; Humans; Indazoles; Magnetic Resonance Imaging; Male; Mice; Mice, Transgenic; Mortality; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Translocation, Genetic; Treatment Outcome; Xenograft Model Antitumor Assays | 2016 |
Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells.
Topics: Apoptosis; Carcinoma; Colorectal Neoplasms; Humans; Indazoles; Mitochondria; Organometallic Compounds; Ruthenium; Salts; Tumor Cells, Cultured | 2005 |
The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells.
Topics: Acetylcysteine; Apoptosis; Cell Line, Tumor; Collagen Type XI; Colorectal Neoplasms; DNA Damage; Dose-Response Relationship, Drug; Humans; Indazoles; Mitochondria; Organometallic Compounds; Oxidative Stress; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Ruthenium Compounds | 2005 |
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Biomedical Research; Breast Neoplasms; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Molecular Structure; Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Piperidines; Prednisolone; Prostatic Neoplasms; Quinazolines; Treatment Outcome | 2007 |
Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in rats.
Topics: Animals; Antineoplastic Agents; Body Weight; Carcinoma; Colorectal Neoplasms; Dose-Response Relationship, Drug; Imidazoles; Indazoles; Male; Organometallic Compounds; Rats; Rats, Inbred Strains; Ruthenium | 1992 |